GlobeNewswire·Nov 6, 2026, 4:01 PM ET

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Company N.V. approved inducement share options for 106,600 ordinary shares granted to 6 non-executive new hires under the 2024 Inducement Plan.
The share options carry an exercise price of $19.56 per share, matching the closing market price on November 2, 2026.
Share options vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 equal monthly installments subject to continued service.
The company also approved restricted stock units for 28,295 ordinary shares granted to the same 6 non-executive new hires on November 2, 2026.
Restricted stock units vest over three years, with one-third vesting on each of the first, second, and third anniversaries of the commencement date subject to continued service.
Both grants comply with Nasdaq Listing Rule 5635(c)(4) to facilitate employee acceptance of employment.
NewAmsterdam is a late-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor, for patients with elevated LDL-C at risk of cardiovascular disease.